Brain metastases trials in China

In China 56 Also abroad 221

56 trials · From ClinicalTrials.gov, checked 15 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-Mutated Lung Cancer
Where
Tianjin
Age
18 years to 75 years
People
74
Run by
Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07505173
Phase 3Taking people
Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.
Where
Beijing
Age
18 years to 80 years
People
134
Run by
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07443397
Phase 2Not yet taking people in China
Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases
Where
Guangzhou
Age
18 years to 75 years
People
45
Run by
The First Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT07413952
Phase 2Taking people
Study on the Treatment of HER2-negative Breast Cancer Brain Metastases With Radiotherapy Combined With Anlotinib
Where
Nanjing
Age
18 years to 70 years
People
39
Run by
The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT07396454
No phaseEnrolling by invitation
Retrospective Multicenter Study of Patient-level T1CE/FLAIR MRI Deep Learning to Predict EGFR/ALK Driver Status in NSCLC Brain Metastases With External Validation and Survival Analysis
Where
Beijing
Age
18 years and over
People
380
Run by
Ming Yang
See details and how to joinNCT07373951
Phase 2Not yet taking people in China
Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study
Where
Tianjin
Age
18 years to 75 years
People
60
Run by
Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07365410
Phase 2Not yet taking people in China
Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases
Where
Hangzhou
Age
18 years to 75 years
People
45
Run by
Zhejiang Cancer Hospital
See details and how to joinNCT07343479
Phase 3Taking people
FSRT Combines With Bevacizumab for Multiple Brain Metastases in Lung Adenocarcinoma
Where
Guangzhou
Age
18 years and over
People
258
Run by
Sun Yat-Sen University Cancer Center
See details and how to joinNCT07058428
No phaseTaking people
Evaluation of Trop-2 ADC in Breast Cancer Patients With Brain Metastases: A Real-World Study
Where
Beijing
Age
18 years and over
People
100
Run by
Peking University Cancer Hospital & Institute
See details and how to joinNCT07251868
Phase 2Taking people
Elimination of PTV Margins Based on MRI-guided Adaptive Stereotactic Radiotherapy for Non-small Cell Lung Cancer With Brain Metastasis
Where
Guangzhou
Age
18 years to 75 years
People
168
Run by
Sun Yat-sen University
See details and how to joinNCT06582940
No phaseTaking people
AI-assisted Diagnosis of Malignant Brain Tumors
Where
Hangzhou
Age
18 years to 100 years
People
3,000
Run by
Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT07198256
Phase 1/2Taking people
A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
Where
Chongqing, Jinan, Shanghai
Age
18 years to 89 years
People
130 worldwide
Run by
Eikon Therapeutics
See details and how to joinNCT06907043
No phaseTaking people
Exploration of the Safety and Efficacy of T-DXd Concurrent With Brain Radiotherapy in Patients With Brain Metastases HER2-positive/HER2-low Advanced Breast Cancer
Where
Beijing
Age
18 years to 75 years
People
40
Run by
QIAO LI
See details and how to joinNCT07117864
No phaseTaking people
Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain Metastases
Where
Hangzhou
Age
18 years and over
People
100
Run by
Innovent Biologics (Suzhou) Co. Ltd.
See details and how to joinNCT07008287
Phase 1/2Taking people
UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases
Where
Changsha
Age
18 years to 70 years
People
30
Run by
Hunan Cancer Hospital
See details and how to joinNCT05535413
Phase 2Taking people
A Clinical Trial of Furmonertinib Combined With Anlotinib as First-line Treatment for Advanced NSCLC With EGFR-sensitive Mutations and Brain Metastasis
Where
Zhengzhou
Age
18 years and over
People
146
Run by
Henan Cancer Hospital
See details and how to joinNCT06945705
Phase 1/2Taking people
Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis
Where
Shanghai
Age
18 years and over
People
74
Run by
Fudan University
See details and how to joinNCT06718933
Phase 2Not yet taking people in China
Heterogeneity of 68Ga-FAPI Uptake As Imaging Biomarker in T-DXd Treatment for Brain Metastasis of HER2 Positive Breast Cancer
Where
Shanghai
Age
18 years and over
People
50
Run by
Fudan University
See details and how to joinNCT06797622
Phase 2Taking people
Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis
Where
Beijing
Age
18 years and over
People
30
Run by
Beijing 302 Hospital
See details and how to joinNCT06418594
Phase 2Taking people
Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases
Where
Changsha
Age
18 years to 75 years
People
20
Run by
Rongrong Zhou
See details and how to joinNCT06702826
No phaseTaking people
AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain Metastases
Where
Shanghai
Age
18 years and over
People
800
Run by
Fudan University
See details and how to joinNCT06604689
Phase 2Not yet taking people in China
A Multicenter, Single-arm, Open-label Study Evaluating the Safety and Efficacy of AK112 Combined With Chemotherapy as First-line Treatment for Non-squamous NSCLC Patients With BRAIN Metastases and Negative Driver Genes (IVO BRAIN)
Where
Guangzhou
People
55
Run by
Sun Yat-sen University
See details and how to joinNCT06684873
Phase 1/2Taking people
TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas
Where
Beijing
Age
16 years to 90 years
People
85
Run by
Essen Biotech
See details and how to joinNCT06640582
Phase 2Taking people
Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain Metastasis
Where
Shanghai
Age
18 years and over
People
54
Run by
Fudan University
See details and how to joinNCT06501391
No phaseTaking people
SRT Combined With Anlotinib for the Treatment of Brain Metastases From Non-small Cell Lung Cancer
Where
Lianyungang
Age
18 years to 80 years
People
46
Run by
The First People's Hospital of Lianyungang
See details and how to joinNCT06476093